Our focus is to improve the lives of people who live with diseases of the central nervous system (CNS). Please read: http://bit.ly/SupernusCommunityGuidelines…
Location: United States, Maryland, Rockville
Employees: 501-1000
Total raised: $42M
Founded date: 2005
Investors 4
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| 22.09.2022 | Internatio... | ibtplc.com |
| 11.03.2021 | Abingworth... | abingworth... |
| - | Horizon Te... | horizontec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.01.2012 | - | $42M | - |
Mentions in press and media 16
| Date | Title | Description |
| 03.08.2026 | Supernus and Indivior Combine to Build $2.2B CNS Biopharmaceutical Company | By Otis D. Sheehan Published: Aug 03 2026, 11:10 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.06.2025 | Wall Street recovers from Friday’s shock as US stocks rise and oil prices ease | Iran’s foreign minister, Abbas Araghchi, appeared to make a veiled outreach for the U.S. to step in and negotiate an end to hostilities between Israel and Iran, saying in a post on X that a phone call from Washington to Israel’s leader “may... |
| 06.03.2024 | Supernus to Participate in Two Upcoming Investor Conferences | - |
| 28.02.2023 | Supernus Announces Fourth Quarter and Full Year 2022 Financial Results | Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021 Fourth quarter 2022 Qelbree® net product sales of $23.6 million increased 29% compared to third quarter of 2022; Full year 2022 Qelbree net product s... |
| 23.11.2021 | Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer | ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supern... |
| 13.10.2021 | Money Moves: Arlington cyber firm Shift5 raised a $20M Series A round | With cyber attacks continuing to hit folks close to home, Arlington, Virginia-based cybersecurity firm Shift5 announced a $20 million Series A round this week. Investors 645 Ventures led the round, with additional funding from Baltimore-bas... |
| 12.10.2021 | SUPERNUS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) | Item 1.01 Entry into a Material Definitive Agreement. On October 10, 2021, Supernus Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Adamas Pharmaceuticals, Inc., a Delaware corporation ("Adamas"), ente... |
| 12.10.2021 | Adamas Pharmaceuticals : Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - Form 8-K | Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio October 11, 2021 n Acquisition of two marketed products diversifies and accelerates revenue and cash flow n Expected to be significantly accr... |
| 11.10.2021 | Adamas Pharmaceuticals : Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio | Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastru... |
| 06.12.2018 | Supernus touts ADHD Phase III data, but results appear to fall short of expectations | CNS-focused Supernus Pharmaceuticals $SUPN reported positive data from keenly watched twin studies testing its non-stimulant ADHD drug in children on Thursday, but the results suggested the treatment does not have a ... |
Show more